natgillin/translations-raw huggingface dataset:
Cardiotoxicity can occur at any time during mitoxantrone therapy, and the risk increases with cumulative dose.
Kardiotoksičnost lahko pojavi kadar koli med zdravljenjem z mitoksantronom, tveganje pa se povečuje s kumulativnim odmerkom.
Novantrone is secreted into breast milk and may cause serious adverse reactions in your baby.
Zdravilo Novantrone se izloča v materino mleko in lahko povzroči resne neželene učinke pri vašem otroku.
Anaphylaxis/anaphylactoid reactions (including shock)
Anafilaksija/anafilaktoidne reakcije (vključno s šokom)
Four patients receiving 140 to 180 mg/m2 as a single bolus injection died as a result of severe leukopenia with infection.
Štirje bolniki, ki so prejeli 140 do 180 mg/m2 v obliki enkratne bolusne injekcije, so umrli zaradi hude levkopenije z okužbo.
Novantrone prevents cancer cells from growing, as a result of which they eventually die.
Zdravilo Novantrone rakavim celicam preprečuje rast, zaradi česar na koncu umrejo.
Active or dormant cardiovascular disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or concomitant use of other cardiotoxic medicinal products may increase the risk of cardiac toxicity.
Aktivna ali mirujoča kardiovaskularna bolezen, predhodno ali sočasno obsevanje mediastinalnega/perikardnega območja, predhodno zdravljenje z drugimi antraciklini ali antracendioni ali sočasna uporaba drugih kardiotoksičnih zdravil lahko povečajo tveganje toksičnosti za srce.
Combining mitoxantrone with potentially cardiotoxic active substances (e.g. anthracyclines) increases the risk of cardiac toxicity.
Kombiniranje mitoksantrona s potencialno kardiotoksičnimi zdravilnimi učinkovinami (npr. antraciklini) poveča tveganje za srčno toksičnost.
If you receive Novantrone to treat multiple sclerosis your doctor will test your heart function before the start of therapy, prior to each subsequent dose and yearly for up to 5 years after the end of therapy.
Če jemljete zdravilo Novantrone za zdravljenje multiple skleroze, bo vaš zdravnik opravljal teste delovanja srca pred začetkom zdravljenja, pred vsakim nadaljnjim odmerkom in vsako leto do 5 let po koncu zdravljenja.
Treatment with mitoxantrone 12 to 14 mg/m² was effective in the treatment of various cancers.
Klinična učinkovitost in varnost Zdravljenje z 12 do 14 mg/m² mitoksantrona je bilo učinkovito pri zdravljenju različnih vrst raka.
Except for the treatment of acute myeloid leukaemia, mitoxantrone therapy generally should not be given to patients with baseline neutrophil counts of less than 1,500 cells/mm3.
Razen za zdravljenje akutne mieloične levkemije se mitoksantrona praviloma ne sme dajati bolnikom z izhodiščnim številom nevtrofilcev manj kot 1.500 celic/mm3.
There have been reports of local/regional neuropathy, some irreversible, following intra-arterial injection.
Obstajajo poročila o lokalni/regionalni nevropatiji, tudi z nepovratnimi posledicami, zaradi intraarterijskega injiciranja.
The following table is suggested as a guide to dosage adjustment, in the treatment of metastatic breast cancer and non-Hodgkin's lymphoma according to haematological nadir (which usually occurs about 10 days after dosing).
Spodnja tabela vsebuje predloge kot smernice prilagajanja odmerkov pri zdravljenju metastatskega raka dojke in ne-Hodgkinovega limfoma glede na hematološko najnižjo raven (ki se običajno pojavi približno 10 dni po dajanju).
Carcinogenic effects were seen in rat and in male mice.
Rakotvorni učinki so bili opaženi pri podganah in mišjih samcih.
The long-term usefulness of mitoxantrone is limited by emerging cancer resistance which ultimately may result in fatal outcome when used as last-line therapy.
Dolgoročno uporabnost mitoksantrona omejuje pojav odpornosti raka, ki se lahko konča s smrtnim izidom, kadar se uporablja kot zdravilo zadnje izbire.
In clinical studies with a dosage of 12 mg/m2 daily for 5 days, patients who achieved a complete remission did so as a result of the first induction course.
V kliničnih študijah z odmerkom 12 mg/m2 vsak dan 5 dni je bila pri bolnikih, ki so dosegli popolno remisijo, ta rezultat prvega kroga indukcijskega zdravljenja.
Mitoxantrone is genotoxic and is considered a potential human teratogen.
Mitoksantron je genotoksičen in velja za potencialno teratogenega pri ljudeh.
Laboratory measurement cannot predict clearance of the active substance and dose adjustments (see section 5.2).
Na podlagi laboratorijskih meritev ni mogoče predvideti očistka zdravilne učinkovine in prilagajanja odmerkov (glejte poglavje 5.2).
Mitoxantrone is excreted slowly in urine and faeces as either unchanged active substance or as inactive metabolites.
Mitoksantron se izloča počasi z urinom in blatom bodisi kot nespremenjena zdravilna učinkovina bodisi kot neaktivni presnovki.
Novantrone concentrate should be slowly injected into a free flowing intravenous infusion of isotonic saline or 5% glucose solution over a period of not less than 3 to 5 minutes.
Koncentrat zdravila Novantrone je treba počasi injicirati v prosto tekočo intravensko infuzijo izotonične fiziološke raztopine ali 5-odstotne raztopine glukoze v obdobju, ki ni krajše od 3 do 5 minut.
The combination of vitamin K antagonists and cytotoxic agents may result in an increased risk of bleeding.
Kombinacija antagonistov vitamina K in citotoksičnih zdravil lahko povzroči povečano tveganje za krvavitve.
Vaccinations and immunisations may not work during treatment with Novantrone and for 3 months after the end of treatment; if you are pregnant or if you and your partner are trying to become pregnant; if you are breast-feeding.
Cepljenje in imunizacija morda ne bosta učinkovita med zdravljenjem z zdravilom Novantrone in 3 mesece po koncu zdravljenja, - če ste noseči ali če s partnerjem poskušata zanositi,
Although patients with severe renal failure have not been studied, mitoxantrone is extensively tissue bound and it is unlikely that the therapeutic effect or toxicity would be mitigated by peritoneal or haemodialysis.
Čeprav niso preučevali bolnikov s hudo ledvično odpovedjo, se mitoksantron v veliki meri veže na tkivo in ni verjetno, da bi peritonealna dializa ali hemodializa ublažili učinek zdravljenja ali toksičnost.
(12 mg/m2 or less) is recommended in patients with inadequate bone marrow reserves e.g. due to prior chemotherapy or poor general condition.
(12 mg/m2 ali manj) se priporoča pri bolnikih s pomanjkljivimi rezervami kostnega mozga, npr. zaradi kemoterapije ali slabega splošnega stanja.
The haematopoietic system was the primary target organ of toxicity showing myelosuppression.
Hematopoetski sistem je bil primarni tarčni organ toksičnosti, kar se odraža z mielosupresijo.
Mitoxantrone in combination with cytarabine as initial induction treatment is at least as effective for inducing remission as daunorubicin combinations in adult patients with previously untreated AML.
Mitoksantron je v kombinaciji s citarabinom v obliki začetnega indukcijskega zdravljenja vsaj tako učinkovit za indukcijo remisije kot kombinacije z daunorubicinom pri odraslih bolnikih s predhodno nezdravljeno
Novantrone has a minor effect on your ability to drive and use machines.
Zdravilo Novantrone ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
In combination regimens mitoxantrone, in starting doses ranging from 7 to 8 to 10 to 12 mg/m2, dependent on the combination and frequency used, has shown effectiveness.
Pri kombiniranem zdravljenju se je mitoksantron, v začetnem odmerku v razponu od 7 do 8 do 10 do 12 mg/m2 , odvisno od kombinacije in pogostosti uporabe, izkazal za učinkovitega.
Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA.
Mitoksantron posega tudi v ribonukleinsko kislino (RNK) in je močan zaviralec topoizomeraze II, encima, odgovornega za odvijanje in popravilo poškodovanega DNK.
A complete blood count, including platelets, should be obtained prior to administration of the initial dose of mitoxantrone, 10 days following the administration and prior to each subsequent infusion and in the event that signs and symptoms of infection develop.
Popolno krvno sliko, vključno s trombociti, je treba pridobiti pred dajanjem začetnega odmerka mitoksantrona, 10 dni po dajanju in pred vsako naslednjo infuzijo ter v primeru pojava znakov in simptomov okužbe.
These reports have included seizures leading to coma and severe neurologic sequelae, and paralysis with bowel and bladder dysfunction.
Ta poročila obsegajo epileptične napade, ki vodijo v komo, in hude nevrološke posledice ter paralizo z disfunkcijo črevesja in sečnega mehurja.
In men, no data are available, but tubular atrophy of the testes and reduced sperm counts were observed in animals (see section 5.3).
Pri moških ni na voljo nobenih podatkov, vendar sta bila pri živalih ugotovljena tubularna atrofija testisov in manjše število spermijev (glejte poglavje 5.3).
Amenorrhoea * Amenorrhea may be prolonged and may be consistent with premature menopause General disorders and administration site conditions Common
Amenoreja * Amenoreja je lahko dolgotrajna in povezana s prezgodnjo menopavzo.
In a pharmacokinetic study in children with de novo acute myeloid leukaemia, ciclosporin co-medication resulted in a 42% decreased clearance of mitoxantrone.
V farmakokinetični študiji pri otrocih z de novo akutno mieloično levkemijo je sočasna uporaba ciklosporina povzročila za 42 % manjši očistek mitoksantrona.
Myocardial toxicity, manifested in its most severe form by potentially irreversible and fatal congestive heart failure (CHF), may occur either during therapy with mitoxantrone or months to years after termination of therapy.
Miokardna toksičnost, ki se v najhujši obliki kaže z morebitno nepopravljivim in smrtnim kongestivnim srčnim popuščanjem, se lahko pojavi bodisi med zdravljenjem z mitoksantronom ali več mesecev ali let po koncu zdravljenja.
The most serious side effects are damage to the heart (myocardial toxicity) and myelosuppression (reduced activity of the bone marrow).
Najresnejši neželeni neželeni učinki so poškodbe srca (miokardna toksičnost) in mielosupresija (zmanjšana aktivnost kostnega mozga).
The recommended initial dosage of Novantrone is 14 mg/m2 of body surface area, given as a single intravenous dose, which may be repeated at 21-day intervals, if your blood values have returned to acceptable levels.
Priporočeni začetni odmerek zdravila Novantrone je 14 mg/m2 telesne površine, dan v enkratnem intravenskem odmerku, ki se lahko ponovi v 21-dnevnih presledkih, če so se vaše krvne vrednosti vrnile na sprejemljivo raven.
If mitoxantrone is administered repeatedly, dosing adjustments should be guided by extent and duration of the reduction in the number of white and red blood cells as well as platelets in your blood.
Če mitoksantron dajemo večkrat, je treba dajanje po obsegu in trajanju prilagajati glede na zmanjšanje števila belih in rdečih krvnih celic ter krvnih ploščic.
Mitoxantrone was not teratogenic in animal studies at doses below human exposure, but caused reproductive toxicity (see section 5.3).
Mitoksantron ni bil teratogen pri raziskavah na živalih pri odmerkih, nižjih od tistih, ki so jim izpostavljeni ljudje, vendar je škodljivo vplival na sposobnost razmnoževanja (glejte poglavje 5.3).
There is no known specific antidote for mitoxantrone.
Za mitoksantron ni znan specifičen antidot.
The maximum lifetime cumulative dose should not exceed 72 mg/m2 (see section 5.1).
Najvišji kumulativni odmerek v celem življenju ne sme preseči 72 mg/m2 (glejte poglavje 5.1).
- Abnormal electrocardiogram.
- nenormalen elektrokardiogram,
Therefore you should avoid becoming pregnant.
Zato se morate izogniti zanositvi.
Mitoxantrone and its metabolites are excreted in bile and urine, but it is not known whether the metabolic or excretory pathways are saturable, may be inhibited or induced, or if mitoxantrone and its metabolites undergo enterohepatic circulation (see section 5.2).
Mitoksantron in njegovi presnovki se izločajo z žolčem in urinom, vendar ni znano, ali lahko na poti presnove in izločanja pride do nasičenja oziroma ali sta poti zavrti ali inducirani, ter ali mitoksantron in njegovi presnovki vstopajo v enterohepatični obtok (glejte poglavje 5.2).
Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone therapy in such patients should be determined before starting therapy.
Zaradi morebitnih nevarnih posledic za srce pri bolnikih, predhodno zdravljenih z daunorubicinom ali doksorubicinom, je treba razmerje med koristmi in tveganostjo zdravljenja z mitoksantronom pri takšnih bolnikih določiti pred začetkom zdravljenja.
Neoplasms benign and malignant (including cysts and polyps) Uncommon
Benigne in maligne neoplazme (vključno s cistami in polipi) Občasni
When used for treatment in other indications mitoxantrone should not be administered during pregnancy in particular during the first trimester of pregnancy.
Pri zdravljenju drugih indikacij naj se mitoksantron ne uporablja med nosečnostjo, zlasti v prvem trimesečju.
Elevated aspartate aminotransferase levels
Povišane vrednosti aspartat aminotransferaze
This medicine might increase the risk for transitory or persistent absence of menstruation (amenorrhoea) in women of childbearing age.
To zdravilo lahko poveča tveganje za začasno ali trajno odsotnost menstruacije (amenoreja) pri ženskah v rodni dobi.
Extravasation can result in tissue necrosis with resultant need for debridement and skin grafting.
Ekstravazacija lahko povzroči nekrozo tkiva s posledično potrebo po odstranitvi odmrlega tkiva in presaditvi kože.
Skin discolouration Tissue necrosis (after extravasation)
Obarvanje kože Nekroza tkiva (po ekstravazaciji)
Plasma accumulation of active substance was not apparent when mitoxantrone was administered either daily for five days or as a single dose every three weeks.
Akumulacije učinkovine v plazmi niso opazili, ko so mitoksantron dajali ali vsakodnevno pet dni ali v enkratnem odmerku vsake tri tedne.
However, in male animals, damage to the testes and decreased sperm counts were observed.
Vendar sta bila pri samcih živali ugotovljena poškodba testisov in manjše število spermijev.
Mitoxantrone has also been used in various combinations for non-Hodgkin's lymphoma; however, data are presently limited and specific regimens cannot be recommended.
Mitoksantron se uporablja tudi v različnih kombinacijah za ne-Hodgkinov limfom; vendar so podatki trenutno omejeni, zato posebnega režima ni mogoče priporočiti.
Cardiac toxicity with mitoxantrone may occur at lower cumulative doses whether or not cardiac risk factors are present.
Srčna toksičnost z mitoksantronom se lahko pojavi pri nižjih kumulativnih odmerkih ne glede na to, ali so prisotni dejavniki tveganja.
Blood tests prior and during treatment with Novantrone Novantrone may affect your blood cell counts.
Krvni testi pred in med zdravljenjem z zdravilom Novantrone Zdravilo Novantrone lahko vpliva na število krvnih celic.
In patients receiving oral anticoagulant therapy, the prothrombin time ratio or INR should be closely monitored with the addition and withdrawal of treatment with mitoxantrone and should be reassessed more frequently during concurrent therapy.
Pri bolnikih, ki se zdravijo s peroralnimi antikoagulanti, je treba skrbno spremljati protrombinski čas ali mednarodno normalizirano razmerje (INR) ob dodajanju in prekinitvi zdravljenja z mitoksantronom ter ga med sočasnim zdravljenjem pogosteje ponovno oceniti.
- Low level of platelets - which may cause bleeding or bruising.
- nizko število krvnih ploščic - kar lahko povzroči krvavitve ali modrice,
Novantrone has also been used in various combinations for non-Hodgkin's lymphoma; however, data are presently limited and specific regimens cannot be recommended.
Zdravilo Novantrone se uporablja tudi v različnih kombinacijah za ne-Hodgkinov limfom; vendar so podatki trenutno omejeni, zato posebnega režima ni mogoče priporočiti.
If this medicinal product is used during pregnancy or if the patient becomes pregnant while taking mitoxantrone, the patient should be informed of the potential risk to the foetus and genetic counselling should be provided.
Če se to zdravilo uporablja med nosečnostjo ali če bolnica zanosi med jemanjem mitoksantrona, jo je treba obvestiti o možnem tveganju za plod in ji zagotoviti genetsko svetovanje.
Women treated with Mitoxantrone have an increased risk of transitory or persistent amenorrhoea and therefore preservation of gametes should be considered prior to therapy.
Za ženske, ki se zdravijo z mitoksantronom, velja povečano tveganje za prehodno ali trajno amenorejo, zato naj pred zdravljenjem razmislijo o shranitvi spolnih celic.
(approximately 5 to 15 minutes) intravenous infusion that may be repeated every 1-3 months.
do 15 minut) intravenske infuzije, ki se lahko ponovi vsakih 1 do 3 mesece.
Elderly patient should receive doses at the low end of the dosing range due to possible reduced liver, kidney or heart function and of possible illness or treatment with other medicines.
Starejši bolniki Starejši bolniki morajo prejemati odmerek pri spodnji meji razpona odmerkov zaradi morebitnega zmanjšanja delovanja jeter, ledvic ali srčne funkcije ter morebitnih bolezni ali zdravljenj z drugimi zdravili.
[To be completed nationally] SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
Mitoxantrone must not be used in treatment of multiple sclerosis in pregnant women (see sections 4.4 and
Mitoksantron se ne sme uporabljati pri zdravljenju multiple skleroze pri nosečnicah (glejte poglavji 4.4 in
In patients administered 15-90 mg/m2, there is a linear relationship between dose and the area under the concentration curve (AUC).
Pri bolnikih, ki so prejeli odmerek 15 do 90 mg/m2, obstaja linearno razmerje med odmerkom in površino pod krivuljo koncentracije.
Mitoxantrone was mutagenic and clastogenic in all in vitro test systems and in rats in vivo.
Mitoksantron je bil mutagen in klastogen v vseh testnih sistemih in vitro ter pri podganah in vivo.
- Reduced activity of the bone marrow.
- zmanjšana aktivnost kostnega mozga.
In the event of an incomplete antileukaemic response, a second induction course may be given with mitoxantrone given for 2 days and cytarabine for 5 days, using the same daily dosage levels.
V primeru nepopolnega antilevkemičnega odziva se lahko da drugi indukcijski krog zdravljenja z mitoksantronom, dajanim 2 dni, in citarabinom, dajani 5 dni, in sicer v enakih dnevnih odmerkih.
If this medicine is used during pregnancy or if you become pregnant while taking this medicine, inform your doctor as there may be risks to the foetus.
Če se to zdravilo jemlje med nosečnostjo ali če zanosite med jemanjem tega zdravila, obvestite svojega zdravnika, saj je zdravilo lahko nevarno za plod.
If severe or life-threatening non haematological toxicity is observed during the first induction course, the second induction course shouldbe withheld until toxicity resolves.
Če je v prvem indukcijskem krogu zdravljenja opaziti hudo ali smrtno nevarno nehematološko toksičnost, je treba z drugim krogom indukcijskega zdravljenja počakati, dokler toksičnost ne mine.
A bluish disolouration of the whites of your eyes, skin and nails may also occur.
Lahko se pojavi tudi modrikasta obarvanost oči, kože in nohtov.
For this reason, the use of mitoxantrone to treat MS is contraindicated for pregnant women (see section 4.3).
Zato je uporaba mitoksantrona pri zdravljenju MS kontraindicirana za nosečnice (glejte poglavje 4.3).
Heart, kidney, gastrointestinal tract, and testes were additional targets.
Srce, ledvice, prebavila in moda so bili dodatne tarče.
Bluish discolouration of the sclera, skin and nails may also occur.
Lahko se pojavi tudi modrikasta obarvanost beločnice, kože in nohtov.
Mitoxantrone in combination with corticosteroids improves pain control, and quality of life in patients with advanced castrate resistant prostate cancer, without any improvement in overall survival.
Mitoksantron v kombinaciji s kortikosteroidi izboljšuje nadzor bolečine in kakovost življenja pri bolnikih z napredovalim rakom prostate, ki se ni odzval na kastracijo, brez kakršnih koli izboljšav v preživetju.
For use as treatment of multiple sclerosis:
Za zdravljenje multiple skleroze:
Single doses ranged from 5 to 12 mg/m2, dose intervals from once per month to once per 3 months.
Posamični odmerki so se gibali od 5 do 12 mg/m2, intervali dajanj pa od 1-krat na mesec do 1-krat na 3 mesece.
Because of the risk of development of secondary malignancies, the benefit-to-risk ratio of mitoxantrone therapy should be determined before starting therapy.
Zaradi tveganja za razvoj sekundarnih malignomov je treba razmerje med koristmi in tveganostjo zdravljenja z mitoksantronom določiti pred začetkom zdravljenja.
Mitoxantrone is contraindicated in women who are breast-feeding (see sections 4.4 and 4.6).
Mitoksantron je kontraindiciran pri doječih ženskah (glejte poglavji 4.4 in 4.6).
Mitoxantrone is indicated for the treatment of acute myeloid leukaemia (AML) in adults.
Mitoksantron je indiciran za zdravljenje akutne mieloične levkemije (AML) pri odraslih.
Cardiac function
Srčna funkcija
Myelosuppresion can be increased when it is used in combination chemotherapy with another myelosuppressive agent such as for treatment of breast cancer.
Mielosupresija se lahko poveča pri uporabi v kombinaciji s kemoterapijo z drugo mielosupresivno učinkovino, kot v primeru zdravljenja raka dojke.
Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks.
Mitoksantron, učinkovina, ki reagira z DNK, tako da se vrine v deoksiribonukleinsko kislino (DNK) prek vodikovih vezi, povzroča navzkrižne povezave in prelome verig.
Mitoxantrone, a synthetic anthracenedione derivative, is an established cytotoxic, antineoplastic agent.
Mitoksantron, sintetični derivat antracena, je uveljavljeno citotoksično, antineoplastično sredstvo.
- Abnormal results of blood tests to check liver function (raised aspartate aminotransferase levels).
- v primeru nenormalnih rezultatov krvnih preiskav potreba po preverjanju funkcij jeter (povišane vrednosti aspartat aminotransferaz).
Myelosuppression may be more severe and prolonged in patients with poor general condition, or prior chemotherapy and/or radiotherapy.
Mielosupresija je lahko hujša in dolgotrajnejša pri bolnikih v slabem splošnem stanju ali pred kemoterapijo in/ali radioterapijo.
What Novantrone looks like and contents of the pack
Izgled zdravila Novantrone in vsebina pakiranja
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine.
Nosečnost, dojenje in plodnost Če ste noseči ali dojite, če menite, da ste noseči, ali če načrtujete nosečnost, se pred uporabo tega zdravila posvetujte s svojim zdravnikom ali farmacevtom.
Paediatric population Safety and efficacy in paediatric patients have not been established.
Pediatrična populacija Varnost in učinkovitost pri pediatričnih bolnikih nista bili dokazani.
Cases of ECG anomalies have been reported.
Srčna toksičnost Poročali so o primerih nepravilnosti na EKG.
Systemic infections should be treated concomitantly with or just prior to commencing therapy with mitoxantrone.
Sistemske okužbe je treba zdraviti sočasno z začetkom zdravljenja z mitoksantronom ali tik pred njim.
Functional cardiac changes may occur in patients with multiple sclerosis treated with mitoxantrone.
Funkcionalne spremembe na srcu se lahko pojavijo pri bolnikih z multiplo sklerozo, zdravljenih z mitoksantronom.
Mitoxantrone in combination regimens is indicated in the remission-induction treatment of blast crisis in chronic myeloid leukaemia.
Mitoksantron je v kombiniranih režimih indiciran za zdravljenje z indukcijo remisije blastne krize pri kronični mieloični levkemiji.